CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 22, 2019-- Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) product platform, today announced the pricing of its initial public offering

CAMBRIDGE, U.K., and BOSTON, Mass., May 9, 2019 –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, today announced two senior appointments to facilitate its expanding and advancing

CAMBRIDGE, U.K., and BOSTON, Mass., May 7, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, today announced a collaboration with the Dementia Discovery Fund (DDF) to use  Bicycle 

CAMBRIDGE, U.K., and BOSTON, Mass., April 24, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, and Oxurion today announced full enrollment of Oxurion’s Phase I trial designed to

CAMBRIDGE, U.K., and BOSTON, Mass., April 24, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, announced today that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will

CAMBRIDGE, U.K., and BOSTON, Mass., April 2, 2019 –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, announced today that Paul Beswick, Ph.D., Bicycle’s Director of UK Chemistry and IP,

CAMBRIDGE, U.K., and BOSTON, Mass., March 29, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, announced today that Bicycle scientists have been selected to present two oral

CAMBRIDGE, U.K., and BOSTON, Mass., March 18, 2019  – Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) product platform, announced today the appointment of Pierre Legault, MBA, CPA, as a Director and

CAMBRIDGE, U.K., and BOSTON, Mass., March 5, 2019 –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, announced today that Gavin Bennett, Ph.D., Bicycle’s Director of Preclinical

Peter Leone Appointed Chief Business Officer Lee Kalowski, Chief Financial Officer, Promoted to U.S. President CAMBRIDGE, U.K., and BOSTON, Mass., February 20, 2019 –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (